Characteristic | With wound drain (group 1, n=99) | Without wound drain (group 2, n=213) | P value |
FIGO stage (n (%)) | 0.072 | ||
I | 6 (6.1) | 18 (8.5) | |
II | 6 (6.1) | 9 (4.2) | |
III | 32 (32.3) | 98 (46.0) | |
IV | 55 (55.6) | 88 (41.3) | |
Histology (n (%)) | |||
HGSC | 71 (71.7) | 149 (72.3) | 0.983 |
Non-HGSC | 28 (28.3) | 57 (27.7) | |
NAC | 48 (48.5) | 54 (25.4) | <0.001 |
Bowel surgery (n (%)) | 47 (47.5) | 73 (34.3) | 0.026 |
Surgical complexity group* (n (%)) | <0.001 | ||
Low | 4 (4.0) | 1 (0.5) | |
Intermediate | 42 (42.4) | 140 (65.7) | |
High | 53 (53.5) | 72 (33.8) | |
Residual disease (n (%)) | 0.833 | ||
No gross residual | 54 (55.1) | 106 (53.8) | |
>0 cm | 44 (44.9) | 91 (46.2) | |
Not available | 1 | 16 | |
Adhesiolysis (n (%)) | 71 (71.7) | 129 (60.6) | 0.056 |
HIPEC (n (%)) | 31 (31.3) | 3 (1.4) | <0.001 |
Duration of surgery (min) (mean±SD) | 481.7±186.9 | 425.9±165.3 | |
Estimated blood loss (mL) (mean±SD) | 1574.9±2095.7 | 1190.2±1235.3 |
*According to Aletti et al. 20
FIGO, International Federation of Gynecology and Obstetrics; HGSC, high grade serous carcinoma; HIPEC, hyperthermic intraperitoneal chemotherapy; NAC, neoadjuvant chemotherapy.